首页> 外文OA文献 >Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma

【2h】

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma

机译：组合型体辐射治疗和酪氨酸激酶抑制剂在转移性肾细胞癌患者中的存活率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yang Liu; Zhiling Zhang; Hui Han; Shengjie Guo; Zhuowei Liu; Mengzhong Liu; Fangjian Zhou; Pei Dong; Liru He;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors [J] . He Liru, Liu Yang, Han Hui, American Journal of Clinical Oncology: Cancer Clinical Trials . 2020,第1期

机译：将酪氨酸激酶抑制剂治疗的转移肾细胞癌患者添加刻膜体放射治疗后的生存结果
2. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy [J] . Ishihara Hiroki, Kondo Tsunenori, Yoshida Kazuhiko, Urologic oncology . 2017,第9期

机译：在第一线酪氨酸激酶抑制剂后进展时间预测接受二线分子靶向治疗的转移性肾细胞癌患者的存活
3. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. [J] . Bracarda S, Bellmunt J, Melichar B, BJU international . 2011,第2期

机译：最初用贝伐单抗加干扰素-α2a治疗并随后用酪氨酸激酶抑制剂治疗的转移性肾细胞癌患者的总生存期：III期AVOREN试验的回顾性分析。
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma [O] . Yang Liu, Zhiling Zhang, Hui Han, 2021

机译：组合型体辐射治疗和酪氨酸激酶抑制剂在转移性肾细胞癌患者中的存活率
7. Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors [O] . Liru He, Yang Liu, Hui Han, 2019

机译：将酪氨酸激酶抑制剂治疗的转移肾细胞癌患者添加立体定位体放射治疗后的存活结果

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma

著录项

引文网络

相似文献

相关主题

期刊订阅